Abstract: A bioactive peptide PCT-1, and preparation method and application thereof are provided. The amino acid sequence of the bioactive peptide PCT-1 is LNRTFE, as shown in SEQ ID NO: 1, and the bioactive peptide PCT-1 has antioxidant and intestinal flora-regulating functions. Extracted from spirulina protein peptides, the bioactive peptide PCT-1 can significantly increase the activities of SOD and GSH-Px in serum, and significantly reduce the content of MDA in serum; its in vivo antioxidant activity is comparable to that of the positive control Trolox. Meanwhile, compared with the blank control group, the bioactive peptide PCT-1 can also reduce the ?-diversity index of intestinal flora, change the overall structure of intestinal flora, regulate the abundance of intestinal flora at various taxonomic levels, and significantly increase the contents of acetic acid and butyric acid. Therefore, the bioactive peptide PCT-1 can be applied in functional foods for antioxidation and intestinal flora regulation.

Abstract: A method, a system, a medium and a device based on multi-spectral data fusion are provided. The method includes: collecting spectrum: collecting NIR spectrum and MIR spectrum of a substance to be detected to obtain a NIR spectrum matrix and a MIR spectrum matrix of the substance to be detected; constructing a detection model; training the detection model; and predicting detection indexes.

Abstract: The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.

Abstract: The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.

Abstract: The present invention provides a fully human anti-VEGF monoclonal antibody, the preparation method and use thereof. The fully human anti-VEGF monoclonal antibody is obtained by using antibody phage display technology, which has higher antibody affinity and stronger capacity for inhibiting tumor cell proliferation in comparison with humanized antibody bevacizumab, and can be used to prepare anti-tumor medicines.

Abstract: The invention provides a fully human anti-HER2 monoclonal antibody, which has an amino acid sequence of heavy chain variable region as shown in SEQ ID NO: 6 and an amino acid sequence of light chain variable region as shown in SEQ ID NO: 8. The invention also discloses the nucleotide sequence encoding the antibody, the expression vector and the host cell comprising the nucleotide sequence, and the use of the antibody for manufacturing the medicament for the treatment of tumor.

Abstract: This invention relates to novel compounds having the formula (I): and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.

Abstract: This invention relates to novel compounds having the formula (I) and to their pharmaceutical compositions and to their methods of use. These novel compounds provide a treatment for cancer.